Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/21827

Title: Estimating costs of care for meningitis infections in low- and middle-income countries
Authors: Portnoy, Allison
Jit, Mark
Lauer, Jeremy
Blommaert, Adriaan
Ozawa, Sachiko
Stack, Meghan
Murray, Jillian
Hutubessy, Raymond
Issue Date: 2015
Citation: VACCINE, 335, p. A240-A247
Abstract: Meningitis infections are often associated with high mortality and risk of sequelae. The costs of treatment and care for meningitis are a great burden on health care systems, particularly in resource-limited settings. The objective of this study is to review data on the costs of care for meningitis in low- and middle-income countries, as well as to show how results could be extrapolated to countries without sound data. We conducted a systematic review of the literature from six databases to identify studies examining the cost of care in low- and middle-income countries for all age groups with suspected, probable, or confirmed meningitis. We extracted data on treatment costs and sequelae by infectious agent and/or pathogen, where possible. Using multiple regression analysis, a relationship between hospital costs and associated determinants was investigated in order to predict costs in countries with missing data. This relationship was used to predict treatment costs for all 144 low- and middle-income countries. The methodology of conducting a systematic review, extrapolating, and setting up a standard database can be used as a tool to inform cost-effectiveness analyses in situations where cost of care data are poor. Both acute and long-term costs of meningitis could be extrapolated to countries without reliable data. Although only bacterial causes of meningitis can be vaccine-preventable, a better understanding of the treatment costs for meningitis is crucial for low- and middle-income countries to assess the cost-effectiveness of proposed interventions in their country. This cost information will be important as inputs in future cost-effectiveness studies, particularly for vaccines. (C) 2014 Elsevier Ltd. All rights reserved.
Notes: [Portnoy, Allison; Ozawa, Sachiko; Murray, Jillian] Johns Hopkins Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. [Jit, Mark] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England. [Jit, Mark] Publ Hlth England, Modelling & Econ Unit, London NW9 5EQ, England. [Lauer, Jeremy; Hutubessy, Raymond] WHO, CH-1211 Geneva 27, Switzerland. [Blornmaert, Adriaan] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, CHERMID, B-2610 Antwerp, Belgium. [Blornmaert, Adriaan] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BIOST, BE-3590 Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/21827
DOI: 10.1016/j.vaccine.2014.11.061
ISI #: 000355034500036
ISSN: 0264-410X
Category: A1
Type: Journal Contribution
Validation: ecoom, 2016
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
published version1.32 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.